Synthetic Biology: Global Markets

Published - Jan 2017| Analyst - John Bergin| Code - BIO066D
Market Research Report Single User License: $6650

Report Highlights

The global synthetic-biology market reached nearly $3.9 billion in 2016 and should reach $11.4 billion by 2021, growing at a compound annual growth rate (CAGR) of 24.0% through 2021.

Report Includes

  • An overview of the global markets for synthetic biology.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Coverage of core synthetic biology products: synthetic genes, other DNA parts, chassis organisms, synthetic cells
  • Coverage of enabling technologies: DNA sequencing, oligonucleotides, specialty media, bioinformatics
  • Coverage of enabled technologies: biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture 
  • Analysis of the synthetic biology industry structure, competitors and intellectual property landscape
  • An assessment of the products and technologies most commercially viable in the immediate and near-future time frame.
  • Profiles of major players in the industry

Report Scope

The study scope includes core synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production systems), enabling technologies (DNA sequencing, DNA synthesis and assembly, genome editing, bioinformatics and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) that are already commercialized or are forecast to be commercialized within the next five years.

We analyze key synthetic-biology technologies and products to determine present and future market status, and forecasted growth from 2016 through 2021. We also discuss strategic alliances, industry structures, competitive dynamics, patents and market driving forces.

BCC Research examines the synthetic-biology industry by market segment, including the following segments: DNA sequencing; DNA synthesis; genome editing; synthetic-biology foundries; industrial biotechnology; pharmaceuticals; and agriculture. The role of key strategic alliances and acquisitions from 2014 through 2016 is discussed. Emerging markets including synthetic genes, synthetic-biology-enabled drugs and vaccines, genome-edited crops, chassis organisms, as well as metabolically engineered factories for producing synthetic fuels and specialty chemicals are analyzed, and more than 135 companies in these fields are highlighted.

Analyst Credentials

BCC Research Analyst

John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.

Select reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at(+1) 781-489-7301 or contact us at
Title/Chapter Name Pages Price
Full Report: Synthetic Biology: Global Markets 266 $6650
Chapter- 1: INTRODUCTION 4 Free Download
Chapter- 2: SUMMARY 3 $250
Chapter- 3: OVERVIEW 10 $375
Chapter- 8: PATENTS 10 $375
Chapter- 9: COMPANY PROFILES 80 $3000
List of Tables
List of Figures
Download Table of Contents
Share This Report